EcoDrugPlus

Amine Oxidase Copper Containing 1

Ensembl ID : ENSFCAG00000031201
Gene Symbol: AOC1
5 Cross references
233 Possible Orthologues:

Amine Oxidase Copper Containing 3

Ensembl ID : ENSFCAG00000025774
Gene Symbol: AOC3
4 Cross references
323 Possible Orthologues:

Amylase Alpha 2b

Ensembl ID : ENSFCAG00000027022
Gene Symbol: AMY2B
4 Cross references
207 Possible Orthologues:

Amyloid P Component, Serum

Ensembl ID : ENSFCAG00000010503
Gene Symbol: APCS
5 Cross references
402 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSFCAG00000001556
Gene Symbol: APP
5 Cross references
279 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSFCAG00000007325
Gene Symbol: AR
5 Cross references
277 Possible Orthologues:

Angiotensin I Converting Enzyme

Ensembl ID : ENSFCAG00000002078
Gene Symbol: ACE
5 Cross references
92 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSFCAG00000000717
Gene Symbol: AGTR1
3 Cross references
214 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSFCAG00000014073
Gene Symbol: AGTR2
5 Cross references
195 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSFCAG00000030589
Gene Symbol: APH1A
5 Cross references
138 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSFCAG00000040244
Gene Symbol: APH1B
5 Cross references
193 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSFCAG00000030869
Gene Symbol: APEX1
5 Cross references
214 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).